XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.88

+0.2%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (16840)	5/3/2004 11:39:02 AM
From: Bluegreen	of 17367

GEORGE!!!!!!!!!!!! Could it be that the BIG GUYS are FINALLY figuring out that RAPTIVA is BETTER than ENBREL for Psoriasis?????? It is a NO BRAINER for which one the PATIENT will choose in my opinion, just can't figure out why it took the analysts or whoever else to figure it out. Why do I say that???? Just look at how MANY people lined up to take Raptiva in the trials when Enbrel was available off label. Anyway with Enbrel out in the open maybe it will get the vast majority of moderate to severe Psoriasis suffers to consider taking BIOLOGICALS!!!! Will be VERY interesting if Raptiva is used OFF LABEL for any other immune response maladies. Maybe it will be ADDED to other meds in a WIDE variety of illnesses.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next